Celgene's second quarter sales increase 22% on 2014

23 July 2015

American biotech company Celgene (Nasdaq: CELG) has reported net product sales of $2.25 billion for the second quarter of 2015, a 22% increase from the same period in 2014.

Adjusted net income for the quarter increased 36% to $1.02 billion, compared to $748 million in the same quarter last year. Adjusted diluted earnings per share in the quarter stood at $1.23, including a $0.06 gain related to the sale of an equity investment on completion of their acquisition by another company. Earnings per share in the second quarter of 2014 was $0.90.

Bob Hugin, chairman and chief executive of Celgene, said: “The Celgene team delivered exceptional results across the portfolio in the second quarter. We continue to invest strategically in the long-term future of Celgene and expect our recently announced transactions with AstraZeneca, Juno and Receptos to accelerate our earnings growth beginning in 2019.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK